1. Show article details.

    Lineage Cell Therapeutics to Present at FORCE Wealth Virtual Fireside Chat on September 23, 2020

    Business Wire – 8:00 AM ET 09/17/2020

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, and Brandi L. Roberts, Chief Financial Officer, will be participating in a FORCE Wealth Virtual Fireside Chat on September 23, 2020 at 12:00 pm Eastern Time / 9:00 am Pacific Time.

  2. Show article details.

    Lineage Cell Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 and at Cantor Virtual Global Healthcare Conference on September 17, 2020

    Business Wire – 8:00 AM ET 09/10/2020

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 at 3:00 pm Eastern Time / 12:00 pm Pacific Time.

  3. Show article details.

    AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes

    Business Wire – 8:00 AM ET 09/09/2020

    AgeX Therapeutics, Inc. (AGE), a company focused on developing and commercializing innovative therapeutics for human aging, and Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, and ES Cell International Pte Ltd., a subsidiary of Lineage, today announced the broadening of their collaborative relationship with regard to ESI...

  4. Show article details.

    Lineage Cell Therapeutics and AgeX Therapeutics Announce Expansion of Agreement Related to ESI Clinical-Grade Pluripotent Stem Cell Lines for Therapeutic Purposes

    Business Wire – 8:00 AM ET 09/09/2020

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, ES Cell International Pte Ltd., a subsidiary of Lineage, and AgeX Therapeutics, Inc. (AGE), a company focused on developing and commercializing innovative therapeutics for human aging, today announced the broadening of their collaborative relationship with regard to ESI ste...

  5. Show article details.

    BRIEF-Lineage Cell Therapeutics Awarded Grant From Israel Innovation Authority For Development Of A Bio-Retinal Patch For Treatment Of Retinal Diseases In Partnership With Precise Bio

    Reuters – 8:48 AM ET 09/08/2020

    Lineage Cell Therapeutics Inc (LCTX): * LINEAGE CELL THERAPEUTICS AWARDED GRANT FROM ISRAEL INNOVATION AUTHORITY FOR DEVELOPMENT OF A BIO-RETINAL PATCH FOR TREATMENT OF RETINAL DISEASES IN PARTNERSHIP WITH PRECISE BIO Source text for Eikon: Further company coverage:

  6. Show article details.

    Lineage Cell Therapeutics Awarded Grant From Israel Innovation Authority for Development of a Bio-Retinal Patch for Treatment of Retinal Diseases in Partnership With Precise Bio

    Business Wire – 8:00 AM ET 09/08/2020

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that the Company has been awarded a new research & development grant for 2020 of up to 1.95 million Israeli New Shekels from the Israel Innovation Authority.

  7. Show article details.

    BRIEF-Lineage Cell Therapeutics- Receives $24.6 Mln Payment From Juvenescence

    Reuters – 9:13 AM ET 08/31/2020

    Lineage Cell Therapeutics Inc (LCTX): * Lineage Cell Therapeutics Inc (LCTX) - RECEIVES $24.6 MILLION PAYMENT FROM JUVENESCENCE LTD. Source text for Eikon: Further company coverage:

  8. Show article details.

    Lineage Cell Therapeutics Receives $24.6 Million Payment From Juvenescence Ltd.

    Business Wire – 9:05 AM ET 08/31/2020

    Additional Capital Provides Over Two Years of Cash Runway Based on Current Business Plan Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced it received $24.6 million in cash from Juvenescence Ltd., representing principal and interest due under a convertible promissory note.

  9. Show article details.

    Lineage Cell Therapeutics to Present at LD Micro 500 Investor Conference and Solebury Trout Zoomside Chat on September 1, 2020

    Business Wire – 8:00 AM ET 08/25/2020

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at the LD Micro 500 Virtual Investor Conference on September 1, 2020 at 9:40 am Eastern Time / 6:40 am Pacific Time.

  10. Show article details.

    BRIEF-Lineage Cell Therapeutics Reports Second Quarter 2020 Financial Results And Provides Update On All Clinical Programs

    Reuters – 5:23 PM ET 08/06/2020

    Lineage Cell Therapeutics Inc (LCTX): * LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES UPDATE ON ALL CLINICAL PROGRAMS. * Q2 REVENUE $400,000 VERSUS $800,000. * Q2 REVENUE ESTIMATE $558,000 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

  11. Show article details.

    Lineage Cell Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on All Clinical Programs

    Business Wire – 4:05 PM ET 08/06/2020

    CARLSBAD, Calif. “Lineage has continued to make significant progress across our entire cell therapy pipeline, with positive milestones on each of our three programs announced this quarter,” stated Brian M. Culley, Lineage CEO.

  12. Show article details.

    Lineage Cell Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020

    Business Wire – 8:00 AM ET 07/30/2020

    Conference Call Scheduled for August 6, 2020 at 5:30pm Eastern Time Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report its second quarter 2020 financial and operating results on Thursday, August 6, 2020, following the close of the U.S. financial markets.

  13. Show article details.

    BRIEF-Lineage Cell Therapeutics Announces Extension Of Opregen Development Grant From Israel Innovation Authority

    Reuters – 8:08 AM ET 07/06/2020

    Lineage Cell Therapeutics Inc (LCTX): * LINEAGE CELL THERAPEUTICS ANNOUNCES EXTENSION OF OPREGEN DEVELOPMENT GRANT FROM ISRAEL INNOVATION AUTHORITY Source text for Eikon: Further company coverage:

  14. Show article details.

    Lineage Cell Therapeutics Announces Extension of OpRegen® Development Grant From Israel Innovation Authority

    Business Wire – 8:00 AM ET 07/06/2020

    Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that as a result of continued clinical progress, the Israel Innovation Authority has extended its previously awarded development grant in support of OpRegen®, the Company’s retinal pigment epithelium cell transplant therapy in development for the treat...

Page:

Today's and Upcoming Events

  • Nov
    11

    LCTX to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    06

    LCTX announced Q2 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.